Background Xpert MTB/RIF (Xpert MTB/RIF) and Xpert MTB/RIF Ultra (Xpert Ultra), the
newest version, are the only World Health Organization (WHO)‐recommended rapid tests …

Background Tuberculosis (TB) is the world's leading infectious cause of death.
Extrapulmonary TB accounts for 15% of TB cases, but the proportion is increasing, and over …

Background Current diagnostics for HIV-associated tuberculosis are suboptimal, with
missed diagnoses contributing to high hospital mortality and approximately 374 000 annual …

Background Most tuberculosis-related deaths in people with HIV could be prevented with
earlier diagnosis and treatment. The only commercially available tuberculosis point-of-care …

Tuberculosis (TB) remains a devastating disease, yet despite its enormous toll on global
health, tools to control TB are insufficient and often outdated. TB Biomarkers (TB‐BM) would …

Background The lateral flow urine lipoarabinomannan (LF‐LAM) assay Alere Determine™
TB LAM Ag is recommended by the World Health Organization (WHO) to help detect active …

Background Xpert MTB/RIF Ultra (Xpert Ultra) and Xpert MTB/RIF are World Health
Organization (WHO)‐recommended rapid nucleic acid amplification tests (NAATs) widely …

Background Xpert MTB/RIF and Xpert MTB/RIF Ultra (Xpert Ultra) are World Health
Organization (WHO)‐recommended rapid tests that simultaneously detect tuberculosis and …

Background Development of rapid biomarker-based tests that can diagnose tuberculosis
using non-sputum samples is a priority for tuberculosis control. We aimed to compare the …

The goals of the End TB strategy, which aims to achieve a 90% reduction in tuberculosis
(TB) incidence and a 95% reduction in TB mortality by 2035, will not be achieved without …